Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495268 | 1.00 | CA2 (0.58) | CA2CA1CA12CA3AR | |
| SCHEMBL9739612 | 0.81 | CA2 (0.51) | CA2CA1CA12CA3AR | |
| SCHEMBL5234213 | 0.78 | CA2 (0.61) | CA2CA1CA12CA3AR | |
| SCHEMBL5241626 | 0.78 | CA2 (0.61) | CA2CA1CA12CA3AR | |
| SCHEMBL19068537 | 0.78 | CA2 (0.61) | CA2CA1CA12CA3AR | |
| SCHEMBL23034643 | 0.78 | CA2 (0.61) | CA2CA1CA12CA3AR | |
| SCHEMBL20049855 | 0.77 | CA2 (0.43) | CA2CA1CA12CA3AR | |
| SCHEMBL9522402 | 0.76 | CA2 (0.46) | CA2CA1CA12CA7CA9 | |
| SCHEMBL9205105 | 0.74 | CA2 (0.40) | CA2CA1CA12CA3AR | |
| SCHEMBL10513096 | 0.74 | CA2 (1.00) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2011101704-A1 | PROCESS FOR PREPARING (4S, 6S)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO-[2,3-B]THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE AND ITS INTERMEDIATES | MICRO LABS LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113804-A1 | Process for Preparing Dorzolamide | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113804-A1 | Process for Preparing Dorzolamide | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| EP-2152718-A2 | PROCESS FOR PREPARING DORZOLAMIDE | Cipla Limited (IN) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135770-A2 | PROCESS FOR PREPARING DORZOLAM IDE | CIPLA LIMITED (IN) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135770-A2 | PROCESS FOR PREPARING DORZOLAM IDE | CIPLA LIMITED (IN) | 2008-11-13 | — | — | WO | disclosed |
| EP-0296879-B1 | SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4863922-A | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0296879-A1 | Substituted aromatic sulfonamides as antiglaucoma agents | MERCK & CO. INC. (US) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113804-A1 | Process for Preparing Dorzolamide | SQOR, PPOX, DAO | CA2 605/4885CA1 196/4885CA12 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.